ArticleGastro hep advances2026
Predicting Clinical Response to Granulocyte/Monocyte Adsorption Apheresis in Treatment-Resistant Ulcerative Colitis.
Article in Gastro hep advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Granulocyte/monocyte adsorption apheresis (GMA) is a nonpharmacological adjuvant therapy for treatment-resistant active ulcerative colitis (UC). Endoscopy is the gold standard for diagnosing and evaluating disease activity and treatment efficacy; however, substitution with blood biomarkers is desirable. We aimed to investigate the correlation between neutrophil/monocyte-associated factors, particularly proteases, and therapeutic responses to GMA in patients with intractable UC. Methods: In this 2-center prospective study conducted at Juntendo University Hospital (Tokyo, Japan) and Juntendo Urayasu Hospital (Chiba, Japan), we included 10 of 12 recruited patients in the final analysis following 10 GMA sessions. GMA is used as an adjunct to conventional medications. Peripheral blood samples were collected before and post-GMA. Results: One month after 10 GMA sessions, 60% of patients showed remission (Lichtiger Clinical Activity Index [CAI]<4), 20% showed treatment effectiveness, and 20% remained unchanged. The neutrophil-to-lymphocyte ratio decreased in 7 participants compared with that in the initial data but did not correlate with CAI changes. Plasminogen levels decreased, whereas tumor necrosis factor-alpha, plasmin-α2-plasmin inhibitor complex, and matrix metalloproteinase-9 (MMP-9) levels increased transiently when precolumn values were compared pre-GMA and post-GMA. However, plasminogen, plasmin-α2-plasmin inhibitor complex, and tumor necrosis factor-alpha levels did not correlate with UC disease severity. Moreover, 80% of patients showed stable or decreased MMP-9 levels across GMA cycles, and MMP-9 changes positively correlated with CAI changes. Only circulating MMP-9 levels positively correlated with CAI changes pre-GMA and post-GMA. Conclusion: Decreased circulating MMP-9 levels predict clinical response to GMA in these patients, possibly serving as a novel and cost-effective biomarker for assessing GMA efficacy and substituting classical clinical parameters.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.